FDA Brief

Warning letters Drugs

FDA warning letter to

Dermacare dba Filler Outlet

High riskIssued Nov 3, 2025Posted Nov 5, 2025Center for Drug Evaluation and Research (CDER)

South Korea's Dermacare, doing business as Filler Outlet, sells unapproved, misbranded injectable botulinum toxin to U.S. consumers through its website.

What happened

FDA reviewed the website www.filleroutlet.com (no facility inspection was made) and found it offering injectable botulinum toxin type A marketed as "Innotox 50u" and "innotox 50 units" to U.S. consumers. The site's claims that the product treats excessive sweating and involuntary eyelid twitching show it is a drug intended for human use, but FDA has no approved application for it. FDA also said the labeling cannot give a layperson adequate directions, because this is a prescription drug that must be given by a licensed practitioner.

What FDA found

  1. The company offers a new drug for sale in the U.S. without an FDA-approved application for it.

    Section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]; section 301(d) [21 U.S.C. § 331(d)]
  2. Offering these drugs to U.S. consumers puts misbranded drugs into interstate commerce.

    Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]
  3. The product labeling does not carry adequate directions for use, which a prescription drug must have.

    Section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5
  4. The drug is not exempt from the adequate-directions requirement, because it is not approved in the U.S.

    21 CFR 201.115(a)
  5. The website's disease-treatment claims show the product is a drug intended for human use.

    21 CFR 201.128
  6. The product is a prescription drug that is not safe for use without a licensed practitioner's supervision.

    Section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]

What FDA wants

FDA tells the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers, and to reply in writing within 15 working days with the steps taken and supporting documents. If corrective action cannot be finished in that time, the company must explain the delay and give a completion date.

Who should pay attention

  • med spas and clinics that buy injectables from online resellers
  • U.S. consumers shopping online for cheaper botulinum toxin
  • importers and distributors of foreign-made injectable drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk